Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients ...
In summary, we believe 2002 is well positioned to be the first approved in vivo CRISPR gene editing treatment, and a truly ...
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback